Baird Upgrades Exactech (EXAC) to Outperform
EXAC Hot Sheet
Rating Summary:4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Baird upgrades Exactech (Nasdaq: EXAC) from Neutral to Outperform. Price target increased from $16 to $22.
To see more analyst ratings on EXAC Click Here.
Exactech, Inc. engages in the development, manufacture, marketing, distribution, and sale of orthopedic implant devices, related surgical instrumentation, and biologic services to hospitals and physicians in the United States and internationally.
To see more analyst ratings on EXAC Click Here.
Exactech, Inc. engages in the development, manufacture, marketing, distribution, and sale of orthopedic implant devices, related surgical instrumentation, and biologic services to hospitals and physicians in the United States and internationally.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Wells Fargo Upgrades Watson Pharmaceuticals (WPI) to Outperform; Actavis Acquisition Adds Growth Prospects
- UPDATE: UBS Upgrades Assured Guaranty (AGO) to Buy; Opportunity Opens After Recent Dip on Moody's Review
Create E-mail Alert Related Categories
UpgradesRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
